Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) BlockadeJuan C. Osorio, Matthew D. Hellmann, Helena A. Yu et al.|Journal of Clinical Oncology|2019Cited by 134
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance statusJoao V. Alessi, Mark M. Awad, Hira Rizvi et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 58